Search Results

ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go 16 employees later this month.

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

Aspen Neuroscience, Inc. has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support clinical research aimed at treating Parkinson’s disease (PD).

Lineage Cell Therapeutics, Inc. today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM).

While many describe California as having a tough life sciences market, there’s some optimism that employment opportunities will improve soon, according to California Life Sciences President and CEO Mike Guerra.

Andelyn Biosciences, Inc. has been selected to manufacture adeno-associated vectors therapies using its suspension AAV Curator™ Platform under the California Institute for Regenerative Medicine Accelerating Medicines Partnership Bespoke Gene Therapy Consortium.

For the first eight months of 2024, California had the most job postings live on BioSpace—37.7% more than Massachusetts. Last year, Massachusetts ranked No.1 for the same time period.

Biocom California, the association representing the California life science industry, released a new report showing California’s life science industry directly provides more than 465,000 jobs in the state and generates $414.2 billion in total business output.

Allogene Therapeutics, Inc. announced that it has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of ALLO-316, an AlloCAR T™ investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma (RCC).